

KİST HİDATİKTE İLAÇ TEDAVİSİ

40. BÖLÜM

Ozan Barış NAMDAROĞLU¹

Giriş

Kist hidatik (KH) tedavisinde amaç hastalığa sebep olan parazitin ara konak formunun etkisiz hale getirilmesi mümkünse vücuttan uzaklaştırılması, hastalığın komplikasyonların önlenerek sorunsuz iyileşmenin sağlanmasıdır. KH için tedavi seçenekleri arasında cerrahi, perkütan tedavi, ilaç tedavisi ve gözlem bulunmaktadır ⁽¹⁻³⁾. Cerrahi KH tedavisi için geleneksel yaklaşım olmuştur; daha sonra alternatif yaklaşımlar getirilmiş ve bazı durumlarda bu yöntemler tercih edilen tedavi olarak cerrahinin yerini almıştır ^(4,5).

İlaç tedavisi 1970'li yıllarda benzimidazol grubu ilaçlardan mebendazolün kullanımıyla başlamış sonraki yıllarda mebendazolün yerini yine aynı gruptan albendazol almıştır ^(6,7). Günümüzde KH hastalığında medikal tedavi cerrahi öncesi ve sonrası, perkütan tedavi öncesi ve sonrası veya izole olarak da uygulanabilmektedir ^(8,9). KH hastalığında progresyonun yavaş olduğu bazı olgularda tedavisiz spontan düzelmeler de görülmektedir ⁽¹⁰⁾.

Medikal Tedavide Kullanılan Ajanlar

Genel bir kural olarak, KH'nin medikal tedavisi için kullanılacak ideal bir ajan parazite (ancak konağa değil) karşı seçici olarak toksik olmalı, hedef

bölgede doku ve intra-kistik düzeylerde etkili bir yanıtı tetikleyecek konsantrasyona ulaşmak için uygun çözünürlük, emilim ve stabilite sağlayacak farmokokinetiğe sahip olmalıdır. Parazitostatik bir etki yerine bir parazitosidal etki göstermesi aynı zamanda en az yan etkiye sahip olması istenilen özelliklerdendir.

Kist hidatiğin medikal tedavisinde, bir benzimidazol-karbamat türevi olan mebendazol ilk kez 1977'de Bekhti tarafından kullanılmıştır ⁽⁶⁾. Daha sonraları aynı gruptan olan albendazol, parbendazol, flubendazol, thiabendazol, cambendazol ve oxfendazol de kullanılmıştır. Bunlardan albendazol kist hidatiğin medikal tedavisinde en başta gelen ilaç değerini kazanmıştır. Sonraki yıllarda değişik ilaçlar denenmiş; ancak bunlardan sadece praziquantel kullanım alanına girebilmiştir ^(1,9,11).

I. Benzimidazoller

İlk olarak 1961 yılında evcil hayvanların gastrointestinal parazitlerine karşı antelmintik ajanlar olarak kullanılmaya başlanan benzimidazol-karbamat bileşikleri (BMZ), günümüzde insan ve veterinerlik tıbbında yaygın olarak kullanılmakta olan heterosiklik aromatik yapıda organik moleküllerdir ⁽¹²⁾. Bu büyük ailenin üyelerinin anti-parazitik (antelmintik dahil), anti-bakteriyel,

¹ Uzm. Dr. Ozan Barış NAMDAROĞLU, S.B.U. İzmir Bozyaka Eğitim Araştırma Hastanesi, Genel Cerrahi, ozannamdaroglu@yahoo.com

Kaynaklar

- Brunetti E, Kern P, Vuitton DA. Writing Panel for the WHO-IWGE, Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. *Acta Trop.* 2010; 114(1):1–16. Doi:10.1016/j.actatropica.2009.11.001
- Stojković M, Weber TF, Jungians T. Clinical management of cystic echinococcosis: state of the art and perspectives. *Curr Opin Infect Dis.* 2018; 31(5):383. Doi: 10.1097/QCO.0000000000000485
- Rinaldi F, Brunetti E, Neumayr A, et al. Cystic echinococcosis of the liver: A primer for hepatologists. *World J Hepatol.* 2014; 6(5):293. Doi: 10.4254/wjh.v6.i5.293
- Dervenis C, Delis S, Avgerinos C, et al. Changing concepts in the management of liver hydatid disease. *J Gastrointest Surg.* 2005; 9(6):869. Doi: 10.1016/j.gassur.2004.10.016
- Rinaldi F, De Silvestri A, Tamarozzi F, et al. Medical treatment versus “Watch and Wait” in the clinical management of CE3b echinococcal cysts of the liver. *BMC Infect Dis.* 2014; 14:492. Doi:10.1186/1471-2334-14-
- Bekhti A, Schaaps JP, Capron M, et al. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. *BrMed J* 1977;2 (6094):1047-51.
- Ammann R, Akovbiantz A, Eckert J. Chemotherapy of human echinococcosis with mebendazole (Vermox):preliminary clinical results] *Schwe iz MedWochenschr* 1979;109(5):148-51.
- Eckert J, Gemmel MA, Meslin FX, et al. WHO/OIE Manual on Echinococcosis in Humans and Animals: a Public Health Problem of Global Concern. Geneva, Paris; 2001.(25/06/2020 tarihinde <https://apps.who.int/iris/handle/10665/42427> adresinden ulaşılmıştır)
- Vuitton DA. Benzimidazoles for the treatment of cystic and alveolar echinococcosis: what is the consensus? *Expert Rev Anti Infect Ther.* 2009; 7(2):145–149. Doi:10.1586/14787210.7.2.145
- Frider B, Larrieu E, Odriozola M. Long-term outcome of asymptomatic liver hydatidosis. *J Hepatol.*1999;30(2):228-31. Doi: 10.1016/s0168-8278(99)80066-x
- Hemphill A, Stadelmann B, Scholl S, Muller J, et al. Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes. *Parasitology.* 2010; 137(3):569–587. Doi:10.1017/S003118200999117X
- Brown HD, Matzuk AR, Ilves IR, et al. Antiparasitic drugs. IV. 2-(4'-Thiazolyl)-benzimidazole, a newanthelmintic. *J AmChemSoc.* 1961; 83(7):1764-1765.
- Keri RS, Hiremathad A, Budagumpi S, et al. Comprehensive review in current developments of benzimidazole based medicinal chemistry. *Chem Biol Drug Des.* 2015; 86(1):19-65. Doi:10.1111/cbdd.12462
- Lacey E. Mode of action of benzimidazoles. *ParasitolToday.* 1990; 6(4):112-115. PMID: 15463312 Doi: 10.1016/0169-4758(90)90227-u.
- Wu XW, Chen XL, Zhang SJ, et al. Pericyst may be a new pharmacological and Therapeutic target for hydatid disease. *Chin Med J (Engl).* 2011(18); 124:2857-2862.
- Sheth UK. Mechanisms of anthelminticaction. *ProgDrugRes.* 1975; 19:147-157.
- Sakai C, Tomitsuka E, Esumi H, et al. Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. *Biochim Biophys Acta.* 2012;1820(5):643-651. Doi:10.1016/j.bbagen.2011.12.013
- El-On J. Benzimidazole treatment of cystic echinococcosis. *Acta Trop.* 2003; 85(2):243–252. Doi: 10.1016/s0001-706x(02)00217-6
- Stojkovic M, Zwahlen M, Teggi A, Vutova K, Cretu CM, Virdone R, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. *PLoS Negl Trop Dis.* 2009; 3(9): e524. Doi :10.1371/journal.pntd.0000524
- Hemphill A, Stadelmann B, Rufener R, et al. Treatment of echinococcosis: albendazole and mebendazole what else? *Parasite.* 2014; 21:70. Doi: 10.1051/parasite/2014073
- Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. *Trans R Soc Trop Med Hyg.* 1989; 83(1):97–102.
- Dawson M, Watson TR. The effect of dose form on the bioavailability of mebendazole in man. *Br J Clin Pharmacol.* 1985; 19(1):87–90. Doi: 10.1111/j.1365-2125.1985.tb02617.x
- Braithwaite PA, Roberts MS, Allan RJ, et al. Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. *Eur J Clin Pharmacol.* 1982(2); 22:161–169. Doi: 10.1007/BF00542462
- Münst GJ, Karlagan G, Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. *Eur J Clin Pharmacol.* 1980; 17(5):375–378. Doi: 10.1007/bf00558451
- Woodtli W, Bircher J, Witassek F, et al. Effect of plasma mebendazole concentrations in the treatment of human echinococcosis. *Am J Trop Med Hyg.* 1985; 34(4):754–760. Doi: 10.4269/ajtmh.1985.34.754.
- Luder PJ, Siffert B, Witassek F, et al. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma meben-

- dazole levels and drug interactions. *Eur J Clin Pharmacol.* 1986; 31:443–448. Doi: 10.1007/BF00613522.
27. Ammann RW, Fleiner-Hoffmann A, Grimm F, et al. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. *J Hepatol.* 1998; 29(6):994–998. Doi: 10.1016/S0168-8278(98)80129-3
 28. Kern P, Dietrich M, Volkmer KJ. Chemotherapy of echinococcosis with mebendazole: clinical observations of 7 patients. *Tropenmed Parasitol.* 1979; 30(1):65–72.
 29. Kung'u A. Glomerulonephritis following chemotherapy of hydatid disease with mebendazole. *East Afr Med J.* 1982; 59(6):404–409.
 30. Kammerer WS, Schantz PM. Long term follow-up of human hydatid disease (*Echinococcus granulosus*) treated with a high-dose mebendazole regimen. *Am J Trop Med Hyg.* 1984; 33(1):132–137. Doi: 10.4269/ajtmh.1984.33.132
 31. Davis A, Pawlowski ZS, Dixon H. Multicentre clinical trials of benzimidazolecarbamates in human echinococcosis. *Bull World Health Organ.* 1986; 64:383–388.
 32. Reuter S, Jensen B, Buttenschoen K, et al. Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature. *J Antimicrob Chemother.* 2000; 46(3):451–456. Doi: 10.1093/jac/46.3.451
 33. de Silva NR, Sirisena JL, Gunasekera DP, et al. Effect of mebendazole therapy during pregnancy on birth outcome. *Lancet.* 1999; 353(9159):1145–1149. Doi: 10.1016/S0140-6736(98)06308-9
 34. Siles-Lucas M, Casulli A, Cirilli R, et al. Progress in the pharmacological treatment of human cystic and alveolar echinococcosis: Compounds and therapeutic targets. *PLOS Negl Trop Dis.* 2018; 12(4):e0006422. Doi: 10.1371/journal.pntd.0006422 X
 35. Dođru D, Kiper N, Ozcelik U, et al. Medical treatment of pulmonary hydatid disease: for which child? *Parasitol Int.* 2005; 54(29):135–138. Doi: 10.1016/j.parint.2005.02.003
 36. Kern P. Human echinococcosis: Follow-up of 23 patients treated with mebendazole. *Infection.* 1983; 11(1):17–24.
 37. Liu CS, Zhang HB, Jiang B, et al. Enhanced bioavailability and cysticidal effect of three mebendazole-oil preparations in mice infected with secondary cysts of *Echinococcus granulosus*. *Parasitol Res.* 2012; 111(3):1205–1211. Doi: 10.1007/s00436-012-2954-2
 38. Todorov T, Vutova K, Mechkov G, et al. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. *Ann Trop Med Parasitol.* 1992; 86(1):59±66. Doi: 10.1080/00034983.1992.11812631
 39. Franchi C, Di Vico B, Teggi A. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. *Clin Infect Dis.* 1999; 29(2):304–309. Doi: 10.1086/520205
 40. Redondo PA, Alvarez AI, Garcia JL, et al. Presystemic metabolism of albendazole: experimental evidence of an efflux process of albendazole sulfoxide to intestinal lumen. *Drug Metab Dispos.* 1999; 27(6):736–740.
 41. Adas G, Arikian S, Kemik O, et al. Use of albendazole sulfoxide, albendazole sulfone, and combined solutions as scolicidal agents on hydatid cysts (in vitro study). *World J Gastroenterol.* 2009; 15(1):112–116. Doi: 10.3748/wjg.15.112
 42. Ingold K, Bigler P, Thormann W, et al. Efficacies of albendazole sulfoxide and albendazole sulfone against in vitro-cultivated *Echinococcus multilocularis* metacestodes. *Antimicrob Agents Chemother.* 1999; 43(5):1052–1061. Doi: 10.1128/AAC.43.5.1052
 43. Li H, Song T, Shao Y, et al. Chemotherapy in alveolar echinococcosis of multiorgans: what's the role? *Parasitol Res.* 2013; 112:2237–2243. Doi: 10.1007/s00436-013-3382-7
 44. Karabulut K, Ozbalci GS, Kesicioglu T, et al. Long-term outcomes of intraoperative and perioperative albendazole treatment in hepatic hydatidosis: single center experience. *Ann Surg Treat Res.* 2014; 87:61–65. <https://doi.org/10.4174/astr.2014.87.2.61>
 45. Salinas JL, Vildozola-Gonzales H, Astuvilca J, et al. Long-term albendazole effectiveness for hepatic cystic echinococcosis. *Am J Trop Med Hyg.* 2011; 85(6):1075–1079. Doi: 10.4269/ajtmh.2011.11-0382
 46. Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. *Trans R Soc Trop Med Hyg.* 2001; 95(1):72–73.
 47. Tamarozzi F, Nicoletti GJ, Neumayr A, et al. Acceptance of standardized ultrasound classification, use of albendazole, and long-term follow-up in clinical management of cystic echinococcosis: a systematic review. *Curr Opin Infect Dis.* 2014; 27(5):425–431. Doi: 10.1097/QCO.0000000000000093
 48. Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. *Eur J Clin Pharmacol.* 1988; 34 (3):315–317.
 49. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. *Int J Nanomedicine.* 2010; 5:101–108. Doi: 10.2147/ijn.s8030 PMID: 20309396
 50. Skuhala T, Trkulja V, Runje M, et al. Albendazole

- sulphoxide concentrations in plasma and hydatid cyst and prediction of parasitological and clinical outcomes in patients with liver hydatidosis caused by *Echinococcus granulosus*. *Croat Med J*. 2014; 55(2):146-155. Doi: 10.3325/cmj.2014.55.146
51. Akhan O, Yildiz AE, Akinci D, et al. Is the adjuvant albendazole treatment really needed with PAIR in the management of liver hydatid cysts? A prospective, randomized trial with short-term follow-up results. *Cardiovasc Intervent Radiol*. 2014; 37(6):1568±1574. Doi:10.1007/s00270-014-0840-2
 52. Todorov T, Vutova K, Petkov D, et al. Albendazole treatment of human cystic echinococcosis. *Trans R Soc Trop Med Hyg*. 1988; 82(3):453-459. Doi: 10.1016/0035-9203(88)90161-7
 53. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. *Acta Trop*. 1997; 64(1-2):79-93. Doi:10.1016/S0001-706X(96)00640-7
 54. Cumino AC, Elissondo MC, Denegri GM. Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in *Echinococcus granulosus* protoscoleces. *Parasitol Int*. 2009; 58(3):270-277. Doi:10.1016/j.parint.2009.03.005 PMID: 19336257
 55. Stitt AW, Fairweather I, Mackender RO. The effect of triclabendazole ("Fasinex") on protein synthesis by the liver fluke, *Fasciola hepatica*. *Int J Parasitol*. 1995; 25(4):421±429. Doi:10.1016/0020-7519(94)00140-J
 56. Hemphill A, Spicher M, Stadelmann B, et al. Innovative chemotherapeutic treatment options for alveolar and cystic echinococcosis. *Parasitology*. 2007;134:1657±1670. <https://doi.org/10.1017/S0031182007003198> PMID: 17631693
 57. Hemphill A, Müller J. Alveolar and cystic echinococcosis: towards novel chemotherapeutic treatment options. *J Helminthol*. 2009; 83(2):99±111. Doi:10.1017/S0022149X0928936X
 58. Gavidia CM, Gonzalez AE, Barron EA, et al. Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: a randomized clinical trial in naturally infected sheep. *PLoS Negl Trop Dis*. 2010; 4(2):e616. Doi:10.1371/journal.pntd.0000616
 59. Alvela-Suañez L, Velasco-Tirado V, Belhasen-Garcia M, A, et al. Safety of the combined use of praziquantel and albendazole in the treatment of human hydatid disease. *Am J Trop Med Hyg*. 2014; 90(5):819±822. Doi:0.4269/ajtmh.13-0059 PMID: 24615131
 60. Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? *Acta Trop*. 2009; 111(2):95-101. Doi:10.1016/j.actatropica.2009.04.006
 61. Elissondo MC, Ceballos L, Alvarez L, et al. Flubendazole and ivermectin in vitro combination therapy produces a marked effect on *Echinococcus granulosus* protoscoleces and metacestodes. *Parasitol Res*. 2009; 105(3):835±842. Doi:10.1007/s00436-009-1469-y
 62. Gavidia CM, Gonzalez AE, Lopera L, et al. Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep. *Am J Trop Med Hyg*. 2009; 80(3):367±372. Doi:10.4269/ajtmh.2009.80.367
 63. Martin RJ. Modes of action of anthelmintic drugs. *Vet J*. 1997; 154(1):11-34.
 64. Ochieng'-Mitula PJ, Burt MD. The effects of ivermectin on the hydatid cyst of *Echinococcus granulosus* after direct injection at laparotomy. *J Parasitol*. 1996; 82(1):155-157. Doi: 10.2307/3284132
 65. Moreno MJ, Casado N, Urrea-Paris MA, et al. Could ivermectin have a synergic effect with albendazole in hydatidosis therapy? *Parasitol Res*. 2002; 88(2):563-567. Doi:10.1007/s00436-001-0519-x
 66. De S, Pan D, Bera AK, et al. In vitro assessment of praziquantel and a novel nanomaterial against protoscoleces of *Echinococcus granulosus*. *J Helminthol*. 2012; 86(1):26±29. Doi:10.1017/S0022149X10000908
 67. Moazeni M, Larki S, Saharkhiz MJ, et al. In vivo study of the efficacy of the aromatic water of *Zataria multiflora* on hydatid cysts. *Antimicrob Agents Chemother*. 2014;58(10):6003-6008. Doi:10.1128/AAC.02963-14
 68. Moazeni M, Larki S, Oryan A, et al. Preventive and therapeutic effects of *Zataria multiflora* methanolic extract on hydatid cyst: An in vivo study. *Vet Parasitol*. 2014; 205(1-2):107±112. Doi:10.1016/j.vetpar.2014.07.006